Delivery Order SPE2DB22D1103-SPE2DB25FTNS0
- Not listed
- The Defense Logistics Agency awarded a $42,647.15 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zepbound 10 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The products will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors valued at $8,651.63. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 27, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections with a ceiling value of $1,586.80. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $8,203.07 under a firm fixed price arrangement. The delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by May 13, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $42,252.91 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors on June 30, 2025, with an ultimate completion date of July 1, 2025. This firm fixed-price delivery order, which carries no set-aside designation, was competitively awarded and represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The performance location for...
- The Defense Logistics Agency awarded a delivery order valued at $16,364.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors on June 2, 2025. This firm fixed-price delivery order, which is scheduled for completion by June 3, 2025, will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen's larger pharmaceutical supply contract vehicle with the DLA. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $15,472.34. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,625.80 on August 7, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This firm fixed price, non-competitive delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania, with completion targeted for August 8, 2025. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTNS0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors valued at $6,130.33. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by June 3, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a brand-name pharmaceutical product used in diabetes and weight management treatment, consistent with AmerisourceBergen's extensive portfolio of specialty medications supplied to federal healthcare systems. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with a broad range of medications, vaccines, medical devices, and specialized healthcare commodities. The company's federal contract history demonstrates consistent capability to meet DLA requirements through open competition, supporting military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 6/2/25 |